Pöördumine

WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ Date: 9 November 2022 REGIONAL OFFICE FOR EUROPE Ms Elen Ohov BUREAU RÉGIONAL DE L’EUROPE REGIONALBÜRO FÜR EUROPA Adviser ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co- Head office: operation Department UN City, Marmorvej 51, Ministry of Social Affairs DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1 Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 Email: [email protected] 10122 Tallinn Website: http://www.euro.who.int Estonia Dear Ms Ohov, Request for information validation: Screening programmes for diabetes and cardiovascular diseases (CVD) Please accept my compliments and allow me to request your support with validating information about screening programmes for diabetes and cardiovascular disease (CVD) in your country. This validation exercise aims to inform the development of three Health Evidence Network (HEN) synthesis reports. HEN synthesis reports provide a summary of the best available evidence and considerations for health policies and interventions. They are available on the WHO website and are indexed on the NCBI Pubmed Bookshelf. The reviews we are working on examine the following topics: 1. the effectiveness of screening programmes for CVD (updating a review published in 2021) 2. the effectiveness of population level screening for diabetes on health outcomes 3. the effectiveness of interventions for prevention of diabetes, once people with intermediate hyperglycaemia are identified through population screening for diabetes We are specifically interested in knowing which countries implement population-level screening, which we define as programmes where each eligible adult within a pre-defined age range is issued an invitation to be screened in a clinical setting at regular intervals. For example, this could include a programme where all adults between age 30 and 70 are invited annually to attend an appointment where their blood pressure or blood glucose levels are measured. Based on this definition, we have identified that your country does not implement population-level screening for cardiovascular disease (e.g. CVD risk factors such as hypertension or preclinical CVDs such as abdominal aortic aneurysm, atrial fibrillation) or diabetes. Could you please confirm whether this is correct, or if you are aware of population-level screening for any of the above taking place, please could you share any details of the programmes, including: UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email: [email protected] DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int Denmark   an overview of the programme (e.g. scope of examination, method of invitation, frequency, age of included adults)  when the programme started  the participation rate (if known) We would very much appreciate your input by 24 November 2022, preferably by email to: [email protected]; [email protected]. If we do not hear back from you by then, we will proceed to finalize the reports with the information we have been able to identify above. Thank you for your time, and please let us know if you have any questions. Yours sincerely, Dr Nino Berdzuli Director Division of Country Health Programmes Copy for information to: Ms Triin Uusberg, Head, European Union Affairs and International Co-operation Department, Ministry of Social Affairs, Suur-Ameerika 1, 10129 Tallinn, Estonia H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative, Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark Ms Kristina Köhler, Liaison Officer, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn, Estonia –2– Saatja: STRANDSBJERG, Anita <[email protected]> Saadetud: 11.11.2022 15:28 Adressaat: Elen Ohov <[email protected]> Koopia: Triin Uusberg <[email protected]>; SM Info <[email protected]>; Ms K. Saarsalu-Layachi <[email protected]>; <[email protected]>; Kaisa.Mitt-Alvarez <[email protected]> Teema: Request for information validation: Screening programmes for diabetes and cardiovascular diseases (CVD) Dear National Counterpart, Please find attached letter from Divisional Director, Country Health Programmes, ref. above subject. Kind regards, Anita Strandsbjerg Country Health Programmes World Health Organization, Regional Office for Europe Marmorvej 51 DK-2100 Copenhagen Denmark Tel &#43;45 4533 6861 E-mail